Human Chorionic Gonadotropin (HCG) Market Size 2025-2029
The human chorionic gonadotropin (HCG) market size is forecast to increase by USD 208.6 million, at a CAGR of 4.6% between 2024 and 2029.
The global human chorionic gonadotropin (HCG) market is expanding due to the increasing prevalence of infertility worldwide. This growing patient pool requires medical interventions where HCG is a cornerstone therapeutic agent, particularly in controlled ovarian stimulation and other assisted reproductive technology (ART) protocols. The market is also influenced by the emerging trend of delayed pregnancies among women, which directly contributes to the rising need for fertility treatments and the expansion of specialized ART centers. In this context, demand for products addressing conditions within the male hypogonadism market is also a contributing factor. The development of advanced injectable formulations and recombinant hcg production methods continues to shape the competitive landscape, meeting the demand for high-purity and consistent products.This growth trajectory is supported by a dynamic landscape of biopharmaceutical manufacturing, with a clear shift towards recombinant dna technology. The market's evolution is essential, as complex regulatory pathways for biosimilar development and approval present a significant challenge for new entrants. These stringent requirements, designed to ensure safety and efficacy in products like the human growth hormone market and human combination vaccines, can delay market entry and limit competition. This regulatory environment necessitates substantial investment in clinical trials and advanced analytical techniques, shaping the strategic focus of companies aiming to introduce more affordable alternatives and address unmet needs in both established and emerging therapeutic areas.
What will be the Size of the Human Chorionic Gonadotropin (HCG) Market during the forecast period?
Explore in-depth regional segment analysis with market size data - historical 2019 - 2023 and forecasts 2025-2029 - in the full report.
Request Free Sample
The market's landscape is defined by the dual dynamics of biopharmaceutical manufacturing innovations and evolving clinical applications. The transition from urinary-derived gonadotropin to recombinant HCG production methods is reshaping supply chain security and product consistency. Concurrently, therapeutic applications are expanding beyond traditional ovulation induction protocols into areas like male hypogonadism therapy. This diversification is supported by advancements in drug delivery systems, including pre-filled pen injectors, which improve patient compliance. The use of advanced analytical techniques, similar to those in human-centric lighting development, is becoming standard for ensuring batch-to-batch consistency.Strategic positioning within this market requires navigating complex regulatory frameworks and addressing the persistent issue of off-label usage. The development of biosimilars faces significant hurdles related to clinical comparability trials and glycan analysis. At the same time, the industry contends with the illicit market, where the product is misused for testicular atrophy mitigation in anabolic steroid cycles. These factors necessitate robust pharmacovigilance standards and supply chain security measures. The principles of automatic generation control and the precision of a programmable logic controller (PLC) can be metaphorically applied to the level of control needed in manufacturing and distribution.
How is this Human Chorionic Gonadotropin (HCG) Industry segmented?
The human chorionic gonadotropin (HCG) industry research report provides comprehensive data (region-wise segment analysis), with forecasts and estimates in "USD million" for the period 2025-2029, as well as historical data from 2019 - 2023 for the following segments.
- Technology
- Natural source extraction
- Recombinant technology
- End-user
- Clinics
- Hospitals
- Diagnostic laboratories
- Route of administration
- Injectable
- Oral
- Nasal spray
- Geography
- North America
- Europe
- Germany
- UK
- France
- Italy
- Spain
- The Netherlands
- Asia
- Rest of World (ROW)
By Technology Insights
The natural source extraction segment is estimated to witness significant growth during the forecast period.
Natural source extraction represents the traditional and largest technology segment, involving the purification of the hormone from biological raw materials. This method's relevance is anchored in its long history of clinical use and well-established regulatory pathways, which fosters trust among some practitioners. This segment accounted for over 65% of the market in the previous year. The primary focus for companies in this space is on enhancing extraction efficiency and purity through advanced purification techniques while managing an ethically sensitive supply chain.
The viability of this segment is dependent on optimizing these traditional processes to compete with recombinant alternatives. Key challenges include inherent vulnerability to supply fluctuations and the escalating costs of maintaining stringent quality control standards for a variable raw material. Strategic initiatives are centered on standardizing collection and auditing the supply chain for urinary-derived gonadotropin to ensure a reliable and high-quality source of active pharmaceutical ingredient (API), thereby justifying its value proposition against newer technologies.
Request Free Sample
The Natural source extraction segment was valued at USD 473.00 million in 2019 and showed a gradual increase during the forecast period.
Regional Analysis
North America is estimated to contribute 40.6% to the growth of the global market during the forecast period.Technavio’s analysts have elaborately explained the regional trends and drivers that shape the market during the forecast period.
Request Free Sample
The market in North America is distinguished by high healthcare expenditure, advanced regulatory frameworks, and a strong preference for innovative biologic therapies. This region, which accounts for over 40% of the global market opportunity, shows significant demand for HCG driven by a high prevalence of infertility and a robust assisted reproductive technology (ART) sector. The market is highly consolidated, with key players competing on product branding, strategic partnerships with large fertility clinics, and direct-to-consumer marketing initiatives where permissible.
The regulatory environment in North America, governed by stringent authorities, requires rigorous clinical data for approval and maintains strict post-market pharmacovigilance standards. Recent guidance has emphasized advanced characterization of glycosylation patterns, a critical quality attribute for HCG bioactivity. This is pushing manufacturers toward more sophisticated analytical techniques for mass spectrometry characterization, reinforcing the position of established players with strong research and development capabilities. The regional strategy revolves around technological leadership, regulatory compliance, and securing distribution channels within a mature, value-based market.
Market Dynamics
Our researchers analyzed the data with 2024 as the base year, along with the key drivers, trends, and challenges. A holistic analysis of drivers will help companies refine their marketing strategies to gain a competitive advantage.
The global market for Human Chorionic Gonadotropin (HCG), a critical injectable hormone for reproductive health, is shaped by two primary production methods: the traditional urinary-derived hcg purification process and the increasingly adopted recombinant technology for hcg synthesis. Ensuring rigorous quality control for urinary-derived products and managing a stable supply chain for biological raw materials are paramount for manufacturers of chorionic gonadotropin for injection USP. This hormone-based injectables for fertility is fundamental in reproductive medicine, with extensive hcg use in ART protocols as one of the primary ovulation-inducing injections for ART. Its applications also include lyophilized injections for luteal support and effective hcg for male infertility treatment. Furthermore, the production of high-purity antigen for immunoassay supports diagnostic applications, underscoring the hormone's dual therapeutic and diagnostic value.Market evolution is driven by the emerging hcg biosimilar approval pathway, although stakeholders must navigate significant regulatory challenges for hcg biosimilars. Innovation is focused on improving user experience through patient self-administration delivery devices and developing advanced formulations for patient compliance. While the market grows, it faces scrutiny over illicit hcg use in bodybuilding and the controversial off-label hcg for weight management. A comprehensive pharmacoeconomic analysis of hcg therapies is crucial for assessing value and guiding market access strategies. Looking forward, the potential for therapeutic expansion beyond fertility represents a significant growth vector, promising to broaden the hormone's clinical applications and market reach.
What are the key market drivers leading to the rise in the adoption of Human Chorionic Gonadotropin (HCG) Industry?
- The primary driver for the market is the rising global prevalence of infertility and the corresponding expansion in the use of assisted reproductive technologies.
A significant factor driving market growth is the increasing prevalence of infertility across global populations. This trend, resulting from a combination of lifestyle factors and delayed parenthood, has created a substantial and growing patient base requiring medical intervention. Human chorionic gonadotropin is a critical therapeutic agent in assisted reproductive technology (ART) cycles for triggering final oocyte maturation, a vital step for successful outcomes. The expanding accessibility of ART services, especially in developing economies, further amplifies demand. This growth in ART cycles, which sees a consistent upward trajectory of over 4% annually in some regions, ensures a stable and growing consumption of HCG, making this a powerful and enduring force in the market.Continuous advancements in biopharmaceutical manufacturing and product innovation represent another critical driver. The industry's shift from urinary-derived gonadotropin to recombinant DNA technology has addressed limitations related to scalability, pathogen risk, and batch-to-batch consistency. Recombinant HCG, produced in controlled environments using chinese hamster ovary (CHO) cells, offers a highly purified and scalable alternative. Beyond the active pharmaceutical ingredient, innovation extends to drug delivery systems, with companies developing patient-friendly formulations like pre-filled pen injectors and auto-injectors. These devices enhance convenience and compliance during lengthy treatment protocols. Strategic industry activities and research into biosimilars are also accelerating the adoption of these advanced technologies, ensuring the market remains dynamic.
What are the market trends shaping the Human Chorionic Gonadotropin (HCG) Industry?
- An emerging trend is the societal shift toward delayed pregnancies, which is coupled with an expansion of assisted reproductive technology centers to meet growing demand.
A primary market trend is the rising incidence of infertility, compounded by societal shifts such as delayed parenthood and lifestyle changes that affect reproductive health. This has led to a significant expansion in the availability and use of assisted reproductive technologies (ART), where ovulation induction protocols are essential. The glycoprotein hormone structure of HCG is critical for final egg maturation and triggering ovulation. In male fertility, it is used for spermatogenesis stimulation. The growing acceptance of these treatments, alongside improving reimbursement scenarios in some developed nations, creates sustained demand. Real-world developments confirm this, with one in six individuals globally affected by infertility during their lifetime, intensifying investment in reproductive health services.Strategic engagement from pharmaceutical companies, through new product approvals and portfolio expansions, is another key trend. This is essential for ensuring product availability, fostering innovation in drug delivery systems, and expanding geographic reach. The biologics and biosimilars sector is particularly dynamic, with companies capitalizing on high-value therapeutics. A favorable regulatory environment for biologics, where over 25% of new approvals in some years fall into this category, encourages market entry. Such activities are a direct response to growing clinical needs. By securing approvals and forming strategic alliances, companies expand the market's capacity and sophistication, like that seen in human resource (HR) technology and saas customer relationship management (CRM) sectors.
What challenges does the Human Chorionic Gonadotropin (HCG) Industry face during its growth?
- A key challenge affecting industry growth involves navigating complex regulatory hurdles and the conundrum surrounding the approval of biosimilars.
The market faces a significant challenge from complex and fragmented regulatory pathways, particularly for the development of biosimilars. Regulatory bodies mandate rigorous analytical and clinical studies to establish biosimilarity, a time-consuming and capital-intensive process. The biological complexity of the glycoprotein hormone makes it difficult to replicate, leading to stringent comparability exercises that can delay market entry for years. This is compounded by divergent requirements across geographic regions, where over 8% of market opportunity is in emerging areas with unique guidelines. This regulatory heterogeneity acts as a barrier to entry, stifling competition and allowing originator products to maintain higher price points, thereby limiting the expansion of more affordable alternatives.A profound and growing challenge is the widespread diversion and illicit use of the product, especially in bodybuilding and performance-enhancing communities. The hormone is often misused in conjunction with anabolic steroid cycles to mitigate testicular atrophy, creating a black-market demand that damages brand integrity and complicates supply chain security. This involves illegal online sales, distribution through unlicensed compounding pharmacies, and frequent product adulteration. This poses significant public health risks and strains regulatory resources. Discussions around scheduling it as a controlled substance in certain jurisdictions are a direct response to this abuse, which could inadvertently create access barriers for patients who rely on it for legitimate medical purposes.
Exclusive Customer Landscape
The human chorionic gonadotropin (HCG) market forecasting report includes the adoption lifecycle of the market, covering from the innovator’s stage to the laggard’s stage. It focuses on adoption rates in different regions based on penetration. Furthermore, the human chorionic gonadotropin (HCG) market report also includes key purchase criteria and drivers of price sensitivity to help companies evaluate and develop their market growth analysis strategies.
Customer Landscape
Key Companies & Market Insights
Companies are implementing various strategies, such as strategic alliances, human chorionic gonadotropin (HCG) market forecast, partnerships, mergers and acquisitions, geographical expansion, and product/service launches, to enhance their presence in the industry.
Abbott Laboratories - The company provides human chorionic gonadotropin (HCG) products, including injectable formulations. These offerings are utilized in therapeutic applications such as fertility treatments and hormone therapy to address specific clinical needs within reproductive and endocrine health.
The industry research and growth report includes detailed analyses of the competitive landscape of the market and information about key companies, including:
- Abbott Laboratories
- Cipla Inc.
- Corona Remedies Pvt. Ltd.
- Emcure Pharmaceuticals Ltd.
- Ferring BV
- Fresenius Kabi AG
- Glenmark Pharmaceuticals Ltd.
- Intas Pharmaceuticals Ltd.
- Lee BioSolutions Inc
- Lijun Pharmaceutical Group Co., Ltd.
- Lupin Ltd.
- Merck and Co. Inc.
- Ningbo Renjian Pharmaceutical Group Co., Ltd
- Organon and Co.
- Sanzyme Pvt. Ltd.
- Scripps Laboratories Inc.
- Serum Institute of India Pvt. Ltd.
- Sun Pharmaceutical Industries Ltd.
- The Cigna Group
- Zydus Lifesciences Ltd.
Qualitative and quantitative analysis of companies has been conducted to help clients understand the wider business environment as well as the strengths and weaknesses of key industry players. Data is qualitatively analyzed to categorize companies as pure play, category-focused, industry-focused, and diversified; it is quantitatively analyzed to categorize companies as dominant, leading, strong, tentative, and weak.
Recent Development and News in Human Chorionic Gonadotropin (HCG) Market
In May 2024, Organon announced its first quarter 2024 financial results, highlighting continued revenue from its established brands portfolio, which includes fertility products such as Pregnyl.In May 2024, Merck KGaA presented new research data from its fertility portfolio at the 10th Congress of the Asia Pacific Initiative on Reproduction (ASPIRE), focusing on advancements in ovarian stimulation protocols.In February 2024, Ferring Pharmaceuticals announced a new collaboration aimed at improving access to reproductive health treatments in low- and middle-income countries, which involves its portfolio of fertility hormones.
Research Analyst Overview
The global human chorionic gonadotropin (HCG) market is witnessing a continuous shift from traditional urinary-derived gonadotropin to recombinant HCG production utilizing recombinant DNA technology and Chinese hamster ovary (CHO) cells. This evolution in biopharmaceutical manufacturing is critical for producing a consistent active pharmaceutical ingredient (API) with a well-defined glycoprotein hormone structure. These advancements directly support key applications in assisted reproductive technology (ART), including in-vitro fertilization and intracytoplasmic sperm injection. In these contexts, HCG is used as an oocyte maturation trigger and for luteal phase support within ovulation induction protocols following the follicular stimulation phase. The pursuit of biosimilar development intensifies the need for rigorous glycan analysis and mass spectrometry characterization.Beyond female infertility, the therapeutic landscape includes male hypogonadism therapy and cryptorchidism treatment, functioning through leydig cell stimulation to support the testosterone production pathway and spermatogenesis stimulation. Innovations in drug delivery systems, such as pre-filled pen injectors and auto-injector devices, are improving administration. However, the market grapples with public health risks stemming from off-label weight loss use and its role in testicular atrophy mitigation during anabolic steroid cycles, often involving compounding pharmacy risks. The industry faces a persistent supply chain vulnerability related to raw material sourcing and the need for stringent GMP audits to maintain batch-to-batch consistency. Market expansion is anticipated, with projections indicating a potential 5% increase in segment value.
Dive into Technavio’s robust research methodology, blending expert interviews, extensive data synthesis, and validated models for unparalleled Human Chorionic Gonadotropin (HCG) Market insights. See full methodology.
|
Market Scope
|
|
Report Coverage
|
Details
|
|
Page number
|
286
|
|
Base year
|
2024
|
|
Historic period
|
2019 - 2023 |
|
Forecast period
|
2025-2029
|
|
Growth momentum & CAGR
|
Accelerating at a CAGR of 4.6%
|
|
Market growth 2024-2029
|
USD 208.6 million
|
|
Market structure
|
Fragmented
|
|
YoY growth 2024-2029(%)
|
4.3%
|
|
Key countries
|
US, Canada, Mexico, Germany, UK, France, Italy, Spain, The Netherlands, China, Japan, India, South Korea, Indonesia, Thailand, Brazil, Saudi Arabia, Argentina, Colombia, UAE, South Africa, Turkey, Israel
|
|
Competitive landscape
|
Leading Companies, Market Positioning of Companies, Competitive Strategies, and Industry Risks
|
Request Free Sample
What are the Key Data Covered in this Human Chorionic Gonadotropin (HCG) Market Research and Growth Report?
- CAGR of the Human Chorionic Gonadotropin (HCG) industry during the forecast period
- Detailed information on factors that will drive the growth and forecasting between 2024 and 2029
- Precise estimation of the size of the market and its contribution of the industry in focus to the parent market
- Accurate predictions about upcoming growth and trends and changes in consumer behaviour
- Growth of the market across North America, Europe, Asia, Rest of World (ROW)
- Thorough analysis of the market’s competitive landscape and detailed information about companies
- Comprehensive analysis of factors that will challenge the human chorionic gonadotropin (HCG) market growth of industry companies
We can help! Our analysts can customize this human chorionic gonadotropin (HCG) market research report to meet your requirements.
Get in touch
1 Executive Summary
- 1 Executive Summary
- 1.1 Market overview
- Executive Summary - Chart on Market Overview
- Executive Summary - Data Table on Market Overview
- Executive Summary - Chart on Global Market Characteristics
- Executive Summary - Chart on Market by Geography
- Executive Summary - Chart on Market Segmentation by Technology
- Executive Summary - Chart on Market Segmentation by End-user
- Executive Summary - Chart on Market Segmentation by Route of Administration
- Executive Summary - Chart on Incremental Growth
- Executive Summary - Data Table on Incremental Growth
- Executive Summary - Chart on Company Market Positioning
2 Technavio Analysis
- 2 Technavio Analysis
- 2.1 Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria
- Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria
- 2.2 Criticality of inputs and Factors of differentiation
- Chart on Overview on criticality of inputs and factors of differentiation
- 2.3 Factors of disruption
- Chart on Overview on factors of disruption
- 2.4 Impact of drivers and challenges
- Chart on Impact of drivers and challenges in 2024 and 2029
3 Market Landscape
- 3 Market Landscape
- 3.1 Market ecosystem
- Chart on Parent Market
- Data Table on - Parent Market
- 3.2 Market characteristics
- Chart on Market characteristics analysis
- 3.3 Value chain analysis
- Chart on Value chain analysis
4 Market Sizing
- 4 Market Sizing
- 4.1 Market definition
- Data Table on Offerings of companies included in the market definition
- 4.2 Market segment analysis
- 4.3 Market size 2024
- 4.4 Market outlook: Forecast for 2024-2029
- Chart on Global - Market size and forecast 2024-2029 ($ billion)
- Data Table on Global - Market size and forecast 2024-2029 ($ billion)
- Chart on Global Market: Year-over-year growth 2024-2029 (%)
- Data Table on Global Market: Year-over-year growth 2024-2029 (%)
5 Historic Market Size
- 5 Historic Market Size
- 5.1 Global Human Chorionic Gonadotropin (HCG) Market 2019 - 2023
- Historic Market Size - Data Table on Global Human Chorionic Gonadotropin (HCG) Market 2019 - 2023 ($ billion)
- 5.2 Technology segment analysis 2019 - 2023
- Historic Market Size - Technology Segment 2019 - 2023 ($ billion)
- 5.3 End-user segment analysis 2019 - 2023
- Historic Market Size - End-user Segment 2019 - 2023 ($ billion)
- 5.4 Route of Administration segment analysis 2019 - 2023
- Historic Market Size - Route of Administration Segment 2019 - 2023 ($ billion)
- 5.5 Geography segment analysis 2019 - 2023
- Historic Market Size - Geography Segment 2019 - 2023 ($ billion)
- 5.6 Country segment analysis 2019 - 2023
- Historic Market Size - Country Segment 2019 - 2023 ($ billion)
6 Qualitative Analysis
- 6 Qualitative Analysis
- 6.1 The Impact of AI on the Global Human Chorionic Gonadotropin (HCG) Market
7 Five Forces Analysis
- 7 Five Forces Analysis
- 7.1 Five forces summary
- Five forces analysis - Comparison between 2024 and 2029
- 7.2 Bargaining power of buyers
- Bargaining power of buyers - Impact of key factors 2024 and 2029
- 7.3 Bargaining power of suppliers
- Bargaining power of suppliers - Impact of key factors in 2024 and 2029
- 7.4 Threat of new entrants
- Threat of new entrants - Impact of key factors in 2024 and 2029
- 7.5 Threat of substitutes
- Threat of substitutes - Impact of key factors in 2024 and 2029
- 7.6 Threat of rivalry
- Threat of rivalry - Impact of key factors in 2024 and 2029
- 7.7 Market condition
- Chart on Market condition - Five forces 2024 and 2029
8 Market Segmentation by Technology
- 8 Market Segmentation by Technology
- 8.1 Market segments
- Chart on Technology - Market share 2024-2029 (%)
- Data Table on Technology - Market share 2024-2029 (%)
- 8.2 Comparison by Technology
- Chart on Comparison by Technology
- Data Table on Comparison by Technology
- 8.3 Natural source extraction - Market size and forecast 2024-2029
- Chart on Natural source extraction - Market size and forecast 2024-2029 ($ billion)
- Data Table on Natural source extraction - Market size and forecast 2024-2029 ($ billion)
- Chart on Natural source extraction - Year-over-year growth 2024-2029 (%)
- Data Table on Natural source extraction - Year-over-year growth 2024-2029 (%)
- 8.4 Recombinant technology - Market size and forecast 2024-2029
- Chart on Recombinant technology - Market size and forecast 2024-2029 ($ billion)
- Data Table on Recombinant technology - Market size and forecast 2024-2029 ($ billion)
- Chart on Recombinant technology - Year-over-year growth 2024-2029 (%)
- Data Table on Recombinant technology - Year-over-year growth 2024-2029 (%)
- 8.5 Market opportunity by Technology
- Market opportunity by Technology ($ billion)
- Data Table on Market opportunity by Technology ($ billion)
9 Market Segmentation by End-user
- 9 Market Segmentation by End-user
- 9.1 Market segments
- Chart on End-user - Market share 2024-2029 (%)
- Data Table on End-user - Market share 2024-2029 (%)
- 9.2 Comparison by End-user
- Chart on Comparison by End-user
- Data Table on Comparison by End-user
- 9.3 Clinics - Market size and forecast 2024-2029
- Chart on Clinics - Market size and forecast 2024-2029 ($ billion)
- Data Table on Clinics - Market size and forecast 2024-2029 ($ billion)
- Chart on Clinics - Year-over-year growth 2024-2029 (%)
- Data Table on Clinics - Year-over-year growth 2024-2029 (%)
- 9.4 Hospitals - Market size and forecast 2024-2029
- Chart on Hospitals - Market size and forecast 2024-2029 ($ billion)
- Data Table on Hospitals - Market size and forecast 2024-2029 ($ billion)
- Chart on Hospitals - Year-over-year growth 2024-2029 (%)
- Data Table on Hospitals - Year-over-year growth 2024-2029 (%)
- 9.5 Diagnostic laboratories - Market size and forecast 2024-2029
- Chart on Diagnostic laboratories - Market size and forecast 2024-2029 ($ billion)
- Data Table on Diagnostic laboratories - Market size and forecast 2024-2029 ($ billion)
- Chart on Diagnostic laboratories - Year-over-year growth 2024-2029 (%)
- Data Table on Diagnostic laboratories - Year-over-year growth 2024-2029 (%)
- 9.6 Market opportunity by End-user
- Market opportunity by End-user ($ billion)
- Data Table on Market opportunity by End-user ($ billion)
10 Market Segmentation by Route of Administration
- 10 Market Segmentation by Route of Administration
- 10.1 Market segments
- Chart on Route of Administration - Market share 2024-2029 (%)
- Data Table on Route of Administration - Market share 2024-2029 (%)
- 10.2 Comparison by Route of Administration
- Chart on Comparison by Route of Administration
- Data Table on Comparison by Route of Administration
- 10.3 Injectable - Market size and forecast 2024-2029
- Chart on Injectable - Market size and forecast 2024-2029 ($ billion)
- Data Table on Injectable - Market size and forecast 2024-2029 ($ billion)
- Chart on Injectable - Year-over-year growth 2024-2029 (%)
- Data Table on Injectable - Year-over-year growth 2024-2029 (%)
- 10.4 Oral - Market size and forecast 2024-2029
- Chart on Oral - Market size and forecast 2024-2029 ($ billion)
- Data Table on Oral - Market size and forecast 2024-2029 ($ billion)
- Chart on Oral - Year-over-year growth 2024-2029 (%)
- Data Table on Oral - Year-over-year growth 2024-2029 (%)
- 10.5 Nasal spray - Market size and forecast 2024-2029
- Chart on Nasal spray - Market size and forecast 2024-2029 ($ billion)
- Data Table on Nasal spray - Market size and forecast 2024-2029 ($ billion)
- Chart on Nasal spray - Year-over-year growth 2024-2029 (%)
- Data Table on Nasal spray - Year-over-year growth 2024-2029 (%)
- 10.6 Market opportunity by Route of Administration
- Market opportunity by Route of Administration ($ billion)
- Data Table on Market opportunity by Route of Administration ($ billion)
11 Customer Landscape
- 11 Customer Landscape
- 11.1 Customer landscape overview
- Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria
12 Geographic Landscape
- 12 Geographic Landscape
- 12.1 Geographic segmentation
- Chart on Market share by geography 2024-2029 (%)
- Data Table on Market share by geography 2024-2029 (%)
- 12.2 Geographic comparison
- Chart on Geographic comparison
- Data Table on Geographic comparison
- 12.3 North America - Market size and forecast 2024-2029
- Chart on North America - Market size and forecast 2024-2029 ($ billion)
- Data Table on North America - Market size and forecast 2024-2029 ($ billion)
- Chart on North America - Year-over-year growth 2024-2029 (%)
- Data Table on North America - Year-over-year growth 2024-2029 (%)
- Chart on Regional Comparison - North America
- Data Table on Regional Comparison - North America
- 12.3.1 US - Market size and forecast 2024-2029
- Chart on US - Market size and forecast 2024-2029 ($ billion)
- Data Table on US - Market size and forecast 2024-2029 ($ billion)
- Chart on US - Year-over-year growth 2024-2029 (%)
- Data Table on US - Year-over-year growth 2024-2029 (%)
- 12.3.2 Canada - Market size and forecast 2024-2029
- Chart on Canada - Market size and forecast 2024-2029 ($ billion)
- Data Table on Canada - Market size and forecast 2024-2029 ($ billion)
- Chart on Canada - Year-over-year growth 2024-2029 (%)
- Data Table on Canada - Year-over-year growth 2024-2029 (%)
- 12.3.3 Mexico - Market size and forecast 2024-2029
- Chart on Mexico - Market size and forecast 2024-2029 ($ billion)
- Data Table on Mexico - Market size and forecast 2024-2029 ($ billion)
- Chart on Mexico - Year-over-year growth 2024-2029 (%)
- Data Table on Mexico - Year-over-year growth 2024-2029 (%)
- 12.4 Europe - Market size and forecast 2024-2029
- Chart on Europe - Market size and forecast 2024-2029 ($ billion)
- Data Table on Europe - Market size and forecast 2024-2029 ($ billion)
- Chart on Europe - Year-over-year growth 2024-2029 (%)
- Data Table on Europe - Year-over-year growth 2024-2029 (%)
- Chart on Regional Comparison - Europe
- Data Table on Regional Comparison - Europe
- 12.4.1 Germany - Market size and forecast 2024-2029
- Chart on Germany - Market size and forecast 2024-2029 ($ billion)
- Data Table on Germany - Market size and forecast 2024-2029 ($ billion)
- Chart on Germany - Year-over-year growth 2024-2029 (%)
- Data Table on Germany - Year-over-year growth 2024-2029 (%)
- 12.4.2 UK - Market size and forecast 2024-2029
- Chart on UK - Market size and forecast 2024-2029 ($ billion)
- Data Table on UK - Market size and forecast 2024-2029 ($ billion)
- Chart on UK - Year-over-year growth 2024-2029 (%)
- Data Table on UK - Year-over-year growth 2024-2029 (%)
- 12.4.3 France - Market size and forecast 2024-2029
- Chart on France - Market size and forecast 2024-2029 ($ billion)
- Data Table on France - Market size and forecast 2024-2029 ($ billion)
- Chart on France - Year-over-year growth 2024-2029 (%)
- Data Table on France - Year-over-year growth 2024-2029 (%)
- 12.4.4 Italy - Market size and forecast 2024-2029
- Chart on Italy - Market size and forecast 2024-2029 ($ billion)
- Data Table on Italy - Market size and forecast 2024-2029 ($ billion)
- Chart on Italy - Year-over-year growth 2024-2029 (%)
- Data Table on Italy - Year-over-year growth 2024-2029 (%)
- 12.4.5 Spain - Market size and forecast 2024-2029
- Chart on Spain - Market size and forecast 2024-2029 ($ billion)
- Data Table on Spain - Market size and forecast 2024-2029 ($ billion)
- Chart on Spain - Year-over-year growth 2024-2029 (%)
- Data Table on Spain - Year-over-year growth 2024-2029 (%)
- 12.4.6 The Netherlands - Market size and forecast 2024-2029
- Chart on The Netherlands - Market size and forecast 2024-2029 ($ billion)
- Data Table on The Netherlands - Market size and forecast 2024-2029 ($ billion)
- Chart on The Netherlands - Year-over-year growth 2024-2029 (%)
- Data Table on The Netherlands - Year-over-year growth 2024-2029 (%)
- 12.5 Asia - Market size and forecast 2024-2029
- Chart on Asia - Market size and forecast 2024-2029 ($ billion)
- Data Table on Asia - Market size and forecast 2024-2029 ($ billion)
- Chart on Asia - Year-over-year growth 2024-2029 (%)
- Data Table on Asia - Year-over-year growth 2024-2029 (%)
- Chart on Regional Comparison - Asia
- Data Table on Regional Comparison - Asia
- 12.5.1 China - Market size and forecast 2024-2029
- Chart on China - Market size and forecast 2024-2029 ($ billion)
- Data Table on China - Market size and forecast 2024-2029 ($ billion)
- Chart on China - Year-over-year growth 2024-2029 (%)
- Data Table on China - Year-over-year growth 2024-2029 (%)
- 12.5.2 Japan - Market size and forecast 2024-2029
- Chart on Japan - Market size and forecast 2024-2029 ($ billion)
- Data Table on Japan - Market size and forecast 2024-2029 ($ billion)
- Chart on Japan - Year-over-year growth 2024-2029 (%)
- Data Table on Japan - Year-over-year growth 2024-2029 (%)
- 12.5.3 India - Market size and forecast 2024-2029
- Chart on India - Market size and forecast 2024-2029 ($ billion)
- Data Table on India - Market size and forecast 2024-2029 ($ billion)
- Chart on India - Year-over-year growth 2024-2029 (%)
- Data Table on India - Year-over-year growth 2024-2029 (%)
- 12.5.4 South Korea - Market size and forecast 2024-2029
- Chart on South Korea - Market size and forecast 2024-2029 ($ billion)
- Data Table on South Korea - Market size and forecast 2024-2029 ($ billion)
- Chart on South Korea - Year-over-year growth 2024-2029 (%)
- Data Table on South Korea - Year-over-year growth 2024-2029 (%)
- 12.5.5 Indonesia - Market size and forecast 2024-2029
- Chart on Indonesia - Market size and forecast 2024-2029 ($ billion)
- Data Table on Indonesia - Market size and forecast 2024-2029 ($ billion)
- Chart on Indonesia - Year-over-year growth 2024-2029 (%)
- Data Table on Indonesia - Year-over-year growth 2024-2029 (%)
- 12.5.6 Thailand - Market size and forecast 2024-2029
- Chart on Thailand - Market size and forecast 2024-2029 ($ billion)
- Data Table on Thailand - Market size and forecast 2024-2029 ($ billion)
- Chart on Thailand - Year-over-year growth 2024-2029 (%)
- Data Table on Thailand - Year-over-year growth 2024-2029 (%)
- 12.6 Rest of World (ROW) - Market size and forecast 2024-2029
- Chart on Rest of World (ROW) - Market size and forecast 2024-2029 ($ billion)
- Data Table on Rest of World (ROW) - Market size and forecast 2024-2029 ($ billion)
- Chart on Rest of World (ROW) - Year-over-year growth 2024-2029 (%)
- Data Table on Rest of World (ROW) - Year-over-year growth 2024-2029 (%)
- Chart on Regional Comparison - Rest of World (ROW)
- Data Table on Regional Comparison - Rest of World (ROW)
- 12.6.1 Brazil - Market size and forecast 2024-2029
- Chart on Brazil - Market size and forecast 2024-2029 ($ billion)
- Data Table on Brazil - Market size and forecast 2024-2029 ($ billion)
- Chart on Brazil - Year-over-year growth 2024-2029 (%)
- Data Table on Brazil - Year-over-year growth 2024-2029 (%)
- 12.6.2 Saudi Arabia - Market size and forecast 2024-2029
- Chart on Saudi Arabia - Market size and forecast 2024-2029 ($ billion)
- Data Table on Saudi Arabia - Market size and forecast 2024-2029 ($ billion)
- Chart on Saudi Arabia - Year-over-year growth 2024-2029 (%)
- Data Table on Saudi Arabia - Year-over-year growth 2024-2029 (%)
- 12.6.3 Argentina - Market size and forecast 2024-2029
- Chart on Argentina - Market size and forecast 2024-2029 ($ billion)
- Data Table on Argentina - Market size and forecast 2024-2029 ($ billion)
- Chart on Argentina - Year-over-year growth 2024-2029 (%)
- Data Table on Argentina - Year-over-year growth 2024-2029 (%)
- 12.6.4 Colombia - Market size and forecast 2024-2029
- Chart on Colombia - Market size and forecast 2024-2029 ($ billion)
- Data Table on Colombia - Market size and forecast 2024-2029 ($ billion)
- Chart on Colombia - Year-over-year growth 2024-2029 (%)
- Data Table on Colombia - Year-over-year growth 2024-2029 (%)
- 12.6.5 UAE - Market size and forecast 2024-2029
- Chart on UAE - Market size and forecast 2024-2029 ($ billion)
- Data Table on UAE - Market size and forecast 2024-2029 ($ billion)
- Chart on UAE - Year-over-year growth 2024-2029 (%)
- Data Table on UAE - Year-over-year growth 2024-2029 (%)
- 12.6.6 South Africa - Market size and forecast 2024-2029
- Chart on South Africa - Market size and forecast 2024-2029 ($ billion)
- Data Table on South Africa - Market size and forecast 2024-2029 ($ billion)
- Chart on South Africa - Year-over-year growth 2024-2029 (%)
- Data Table on South Africa - Year-over-year growth 2024-2029 (%)
- 12.6.7 Turkey - Market size and forecast 2024-2029
- Chart on Turkey - Market size and forecast 2024-2029 ($ billion)
- Data Table on Turkey - Market size and forecast 2024-2029 ($ billion)
- Chart on Turkey - Year-over-year growth 2024-2029 (%)
- Data Table on Turkey - Year-over-year growth 2024-2029 (%)
- 12.6.8 Israel - Market size and forecast 2024-2029
- Chart on Israel - Market size and forecast 2024-2029 ($ billion)
- Data Table on Israel - Market size and forecast 2024-2029 ($ billion)
- Chart on Israel - Year-over-year growth 2024-2029 (%)
- Data Table on Israel - Year-over-year growth 2024-2029 (%)
- 12.7 Market opportunity by geography
- Market opportunity by geography ($ billion)
- Data Tables on Market opportunity by geography ($ billion)
13 Drivers, Challenges, and Opportunity
- 13 Drivers, Challenges, and Opportunity
- 13.1 Market drivers
- Rising global prevalence of infertility and expanding utilization of ART
- Technological advancements and product innovation in biopharmaceutical production
- Expanding therapeutic applications and growing off-label usage
- 13.2 Market challenges
- Regulatory hurdles and biosimilar conundrum
- Intensifying threat of product diversion and illicit use
- Supply chain vulnerabilities and raw material sourcing constraints
- 13.3 Impact of drivers and challenges
- Impact of drivers and challenges in 2024 and 2029
- 13.4 Market opportunities
- Emerging trend of delayed pregnancies among women coupled with expanding ART centers
- Strategic product approvals and intensifying pharmaceutical sector engagement
- Growing disposable income and healthcare expenditure in emerging economies
14 Competitive Landscape
- 14 Competitive Landscape
- 14.1 Overview
- 14.2 Competitive Landscape
- Overview on criticality of inputs and factors of differentiation
- 14.3 Landscape disruption
- Overview on factors of disruption
- 14.4 Industry risks
- Impact of key risks on business
15 Competitive Analysis
- 15 Competitive Analysis
- 15.1 Companies profiled
- 15.2 Company ranking index
- 15.3 Market positioning of companies
- Matrix on companies position and classification
- 15.4 Abbott Laboratories
- Abbott Laboratories - Overview
- Abbott Laboratories - Business segments
- Abbott Laboratories - Key news
- Abbott Laboratories - Key offerings
- Abbott Laboratories - Segment focus
- SWOT
- 15.5 Cipla Inc.
- Cipla Inc. - Overview
- Cipla Inc. - Business segments
- Cipla Inc. - Key news
- Cipla Inc. - Key offerings
- Cipla Inc. - Segment focus
- SWOT
- 15.6 Corona Remedies Pvt. Ltd.
- Corona Remedies Pvt. Ltd. - Overview
- Corona Remedies Pvt. Ltd. - Product / Service
- Corona Remedies Pvt. Ltd. - Key offerings
- SWOT
- 15.7 Emcure Pharmaceuticals Ltd.
- Emcure Pharmaceuticals Ltd. - Overview
- Emcure Pharmaceuticals Ltd. - Product / Service
- Emcure Pharmaceuticals Ltd. - Key offerings
- SWOT
- 15.8 Ferring BV
- Ferring BV - Overview
- Ferring BV - Product / Service
- Ferring BV - Key news
- Ferring BV - Key offerings
- SWOT
- 15.9 Fresenius Kabi AG
- Fresenius Kabi AG - Overview
- Fresenius Kabi AG - Product / Service
- Fresenius Kabi AG - Key offerings
- SWOT
- 15.10 Glenmark Pharmaceuticals Ltd.
- Glenmark Pharmaceuticals Ltd. - Overview
- Glenmark Pharmaceuticals Ltd. - Product / Service
- Glenmark Pharmaceuticals Ltd. - Key offerings
- SWOT
- 15.11 Intas Pharmaceuticals Ltd.
- Intas Pharmaceuticals Ltd. - Overview
- Intas Pharmaceuticals Ltd. - Product / Service
- Intas Pharmaceuticals Ltd. - Key offerings
- SWOT
- 15.12 Lee BioSolutions Inc
- Lee BioSolutions Inc - Overview
- Lee BioSolutions Inc - Product / Service
- Lee BioSolutions Inc - Key offerings
- SWOT
- 15.13 Lijun Pharmaceutical Group Co., Ltd.
- Lijun Pharmaceutical Group Co., Ltd. - Overview
- Lijun Pharmaceutical Group Co., Ltd. - Product / Service
- Lijun Pharmaceutical Group Co., Ltd. - Key offerings
- SWOT
- 15.14 Lupin Ltd.
- Lupin Ltd. - Overview
- Lupin Ltd. - Business segments
- Lupin Ltd. - Key news
- Lupin Ltd. - Key offerings
- Lupin Ltd. - Segment focus
- SWOT
- 15.15 Merck and Co. Inc.
- Merck and Co. Inc. - Overview
- Merck and Co. Inc. - Business segments
- Merck and Co. Inc. - Key news
- Merck and Co. Inc. - Key offerings
- Merck and Co. Inc. - Segment focus
- SWOT
- 15.16 Ningbo Renjian Pharmaceutical Group Co., Ltd
- Ningbo Renjian Pharmaceutical Group Co., Ltd - Overview
- Ningbo Renjian Pharmaceutical Group Co., Ltd - Product / Service
- Ningbo Renjian Pharmaceutical Group Co., Ltd - Key offerings
- SWOT
- 15.17 Organon and Co.
- Organon and Co. - Overview
- Organon and Co. - Product / Service
- Organon and Co. - Key offerings
- SWOT
- 15.18 Sanzyme Pvt. Ltd.
- Sanzyme Pvt. Ltd. - Overview
- Sanzyme Pvt. Ltd. - Product / Service
- Sanzyme Pvt. Ltd. - Key offerings
- SWOT
16 Appendix
- 16 Appendix
- 16.1 Scope of the report
- Market definition
- Objectives
- Notes and caveats
- 16.2 Inclusions and exclusions checklist
- Inclusions checklist
- Exclusions checklist
- 16.3 Currency conversion rates for US$
- Currency conversion rates for US$
- 16.4 Research methodology
- 16.5 Data procurement
- 16.6 Data validation
- 16.7 Validation techniques employed for market sizing
- Validation techniques employed for market sizing
- 16.8 Data synthesis
- 16.9 360 degree market analysis
- 360 degree market analysis
- 16.10 List of abbreviations
Research Framework
Technavio presents a detailed picture of the market by way of study, synthesis, and summation of data from multiple sources. The analysts have presented the various facets of the market with a particular focus on identifying the key industry influencers. The data thus presented is comprehensive, reliable, and the result of extensive research, both primary and secondary.
INFORMATION SOURCES
Primary sources
- Manufacturers and suppliers
- Channel partners
- Industry experts
- Strategic decision makers
Secondary sources
- Industry journals and periodicals
- Government data
- Financial reports of key industry players
- Historical data
- Press releases
DATA ANALYSIS
Data Synthesis
- Collation of data
- Estimation of key figures
- Analysis of derived insights
Data Validation
- Triangulation with data models
- Reference against proprietary databases
- Corroboration with industry experts
REPORT WRITING
Qualitative
- Market drivers
- Market challenges
- Market trends
- Five forces analysis
Quantitative
- Market size and forecast
- Market segmentation
- Geographical insights
- Competitive landscape
Get the report (PDF) sent to your email within minutes.
Complimentary full Excel data with your report purchase.
